2024-11-18 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**1. Performance Comparison & Alpha/Beta Analysis:**

Vertex Pharmaceuticals Inc. (VRTX) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases.

The cumulative return for VRTX is 175.34%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 123.86%. The difference is 51.48%, placing it at the 74th percentile of its historical performance range relative to the S&P 500 (based on a minimum difference of -69.76% and a maximum of 94.07%).


The Alpha/Beta analysis reveals significant outperformance (high alpha) and high sensitivity to market movements (high beta) in earlier periods (2015-2019), which has moderated in recent years. The consistently high CAGR (Compound Annual Growth Rate) reflects strong growth.  However, the significant MDD (Maximum Drawdown) values, particularly in 2019-2021, highlight periods of substantial risk.  Market capitalization has steadily increased over the analyzed period.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.8% | 32.2% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 31.5% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.1% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.4% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 34.7% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 34.7% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 21.3% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 109.3% | 18.8% | 81.4% | 0.6 | 124.6 |


**2. Recent Price Movement:**

* Closing Price: $465.7
* 5-Day Moving Average: $487.2
* 20-Day Moving Average: $483.15
* 60-Day Moving Average: $477.22

The price is currently below all three moving averages, suggesting a potential downward trend.


**3. Technical Indicators and Expected Return:**

* RSI: 46.04 (Approaching oversold territory, but not decisively so)
* PPO: -0.32 (Negative, indicating bearish momentum)
* 20-Day Relative Strength Change: -6.82% (Short-term downward trend)
* Expected Return (Long-term, 2+ years vs. S&P 500): 8.89%

The current price of $465.69 is not significantly far removed from recent highs or lows; therefore, no sharp upward or downward trends have been observed recently.


**4. Recent Financial Performance:**

The provided EPS data shows significant volatility, with a large negative EPS reported on 2024-08-02.  Further analysis and understanding of the context behind this outlier (e.g., one-time charges) is needed.  Revenue has shown steady growth, despite the EPS fluctuation.  A comparison with analyst expectations for the most recent earnings report is crucial for a complete assessment.


| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-11-05 | 4.05     | $2.77 B      |
| 2024-08-02 | -13.92   | $2.65 B      |
| 2024-05-07 | 4.26     | $2.69 B      |
| 2023-11-07 | 4.01     | $2.48 B      |
| 2024-11-05 | 4.01     | $2.48 B      |


**6. Financial Information:**

The provided financial data shows high and relatively stable profit margins, suggesting strong profitability.  ROE (Return on Equity) fluctuates, with some negative quarters, highlighting potential risks or periods of reinvestment.  Further analysis is needed to understand the drivers of these fluctuations.

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30  | $2.77B     | 85.84%        |
| 2024-06-30  | $2.65B     | 85.94%        |
| 2024-03-31  | $2.69B     | 87.27%        |
| 2023-12-31  | $2.52B     | 85.38%        |
| 2023-09-30  | $2.48B     | 87.17%        |

**Capital and Profitability:**

| Quarter     | Equity     | ROE          |
|-------------|------------|--------------|
| 2024-09-30  | $15.63B    | 6.69%         |
| 2024-06-30  | $14.77B    | -24.32%       |
| 2024-03-31  | $18.55B    | 5.93%         |
| 2023-12-31  | $17.58B    | 5.51%         |
| 2023-09-30  | $16.51B    | 6.27%         |



**7. News and Recent Issues:**

*Information on recent earnings news (within the last 2 days) from sources like Shacknews and analyst opinions from FINBOLD is missing from the provided data and needs to be added for a comprehensive analysis.*  This would include details on whether the recent earnings met or beat expectations and the overall market outlook for VRTX.

**8. Overall Summary:**

VRTX has demonstrated significant long-term growth, substantially outperforming the S&P 500. However, periods of high volatility and drawdown highlight considerable risk.  The recent price movement suggests a potential downward trend, although the RSI is not deeply oversold.  A thorough analysis of the most recent earnings report and comparison with analyst expectations, along with recent news and market sentiment from reputable sources, is crucial for a complete picture. The high profit margins are positive, but fluctuating ROE requires further investigation.  The long-term expected return of 8.89% relative to the S&P 500 is attractive, but investors should consider the inherent volatility.


**9. Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.  The accuracy of the data used in this analysis depends entirely on the accuracy of the information provided.
